Description
3,4-Difluorobenzocurcumin is a derivative of curcumin that, like its parent compound, may display antioxidative, anti-inflammatory, chemopreventive, and antibacterial activities.
| Product Unit Size | Cost | Quantity | Stock |
|---|
3,4-Difluorobenzocurcumin is a derivative of curcumin that, like its parent compound, may display antioxidative, anti-inflammatory, chemopreventive, and antibacterial activities.
| Cas No. | 1170354-22-9 |
|---|---|
| Purity | ≥95% |
| Formula | C28H22F2O6 |
| Formula Wt. | 492.47 |
| Chemical Name | (1E,6E)-1,7-bis-(4-hydroxy-3-methosyphenyl) hepta-1,6-diene [4(3,4-difluorobenzaldehyde)]-3,5-dione |
| IUPAC Name | (1E,6E)-4-[(3,4-difluorophenyl)methylidene]-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione |
| Synonym | Difluorobenzocurcumin, 3,4-Difluorobenzocurcumin, CDF |
| Melting Point | 214-217°C |
| Solubility | DMSO, 110mg/mL |
| Appearance | Bright Yellow Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures | |
Okuda KS, Ng MF, Ruslan NF, et al. 3,4-Difluorobenzocurcumin inhibits Vegfc-Vegfr3-Erk signalling to block developmental lymphangiogenesis in zebrafish. Pharmaceuticals (Basel). 2021 Jun 26;14(7):614. PMID: 34206901.
Endogenous opioid peptide; μOR agonist.
p110α PI3K inhibitor.
μOR and δOR agonist, D2/D3 DA potentiator.
Mycotoxin derivative; actin polymerization inhi...
FAAH inhibitor.
GPR84 agonist.
Endogenous vitamin D prodrug.
NSAID; COX-1/2 and PDE inhibitor.
Sulfonylurea; ATP-sensitive K+ channel blocker....
N-Des-2-methylpropan-2-ol Docetaxel is an impur...
OVA antigen.
V600E B-Raf inhibitor.
Corticosteroid
FLT3, PDGFR, c-Kit inhibitor.
Mycotoxin produced by Alternaria; topoisomerase...
Endogenous peptide, involved in stress signalin...
Promotes Aβ clearance.
VEGFR2, PDGFR, FGFR2 inhibitor.
Flavone found in Teucrium.
Peptide hormone found in eels; GnRH agonist, we...